Am J Blood Res 2013;3(3):260-264
Brief Communication
Romiplostim for delayed platelet recovery and secondary thrombocy-topenia
following allogeneic stem cell transplantation
Limei Michelle Poon, Antonio Di Stasi, Uday Popat, Richard E Champlin, Stefan O Ciurea
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center,
Houston, Texas, USA; Department Of Hematology-Oncology, National University Cancer Institute, Singapore
Received May 24, 2013; Accepted July 27, 2013; Epub August 19, 2013; Published August 30, 2013
Abstract: Delayed recovery of platelet count post allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been
associated with worse transplant outcomes. Thrombopoietic agents have been successfully used in immune mediated
thrombocytopenia or thrombocytopenia from bone marrow failure syndromes; however, the experience regarding their use
after allo-HSCT is limited. Here we report on the safety and efficacy of romiplostim used in 3 consecutive patients with
thrombocytopenia post allogeneic transplantation. Two patients had prolonged platelet recovery due to poor graft function
while one had secondary failure of platelet recovery, likely immune mediated, post transplantation. Successful use of such
agents post-transplant may improve platelet recovery, decrease rates of complications and potentially improve outcomes.
(AJBR1305003).
Keywords: Post-transplant thrombocytopenia, romiplostim, allogeneic hematopoietic stem cell transplantation
Address correspondence to: Dr. Stefan O Ciurea, The University of Texas MD Anderson Cancer Center, 1515 Holcombe
Blvd., Unit 423, Hou-ston, Texas, 77030. Tel: 713-745-0146; Fax: 713-794-4902; E-mail: sciurea@mdanderson.org
Brief Communication
Romiplostim for delayed platelet recovery and secondary thrombocy-topenia
following allogeneic stem cell transplantation
Limei Michelle Poon, Antonio Di Stasi, Uday Popat, Richard E Champlin, Stefan O Ciurea
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center,
Houston, Texas, USA; Department Of Hematology-Oncology, National University Cancer Institute, Singapore
Received May 24, 2013; Accepted July 27, 2013; Epub August 19, 2013; Published August 30, 2013
Abstract: Delayed recovery of platelet count post allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been
associated with worse transplant outcomes. Thrombopoietic agents have been successfully used in immune mediated
thrombocytopenia or thrombocytopenia from bone marrow failure syndromes; however, the experience regarding their use
after allo-HSCT is limited. Here we report on the safety and efficacy of romiplostim used in 3 consecutive patients with
thrombocytopenia post allogeneic transplantation. Two patients had prolonged platelet recovery due to poor graft function
while one had secondary failure of platelet recovery, likely immune mediated, post transplantation. Successful use of such
agents post-transplant may improve platelet recovery, decrease rates of complications and potentially improve outcomes.
(AJBR1305003).
Keywords: Post-transplant thrombocytopenia, romiplostim, allogeneic hematopoietic stem cell transplantation
Address correspondence to: Dr. Stefan O Ciurea, The University of Texas MD Anderson Cancer Center, 1515 Holcombe
Blvd., Unit 423, Hou-ston, Texas, 77030. Tel: 713-745-0146; Fax: 713-794-4902; E-mail: sciurea@mdanderson.org
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |